Celldex Discontinues Barzolvolimab Development in Prurigo Nodularis After Phase 2 Failure
Celldex discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints.
/ 220 items
#andre↓
PolyPid Secures $320 Million Partnership with Azurity for D-PLEX100 in U.S. and Canada
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Crypto Markets Rally as CLARITY Act Nears Senate Floor Vote After White House Ethics Breakthrough
Bitcoin and Coinbase surge after Bessent signals the CLARITY Act is close to passage. White House ethics agreement removes final hurdle ahead of August recess.
Apple Partners with Klarna for New “Apple Upgrade” Device Leasing Program
The program covers most iPhones, Macs, iPads, and Apple Watches.
Jupiter Neurosciences Expands CNS Pipeline with ALA-002 Licensing Deal Worth Up to $100M
The deal adds a differentiated psychedelic asset to Jupiter’s CNS pipeline.